NewsRoom Articles - Page 73 of 154 - PsychedelicNewsWire (PNW)

MondayJan 10, 2022 1:36 pm

University of Texas-Austin Launches Center for Psychedelic Research and Therapy

The University of Texas at Austin recently established a Center for Psychedelic Research and Therapy. This comes months after the state’s governor signed a proposal that instructs the state to conduct research on the benefits and risks of ketamine, MDMA and psilocybin for veterans. Prof. Charles B. Nemeroff, the center’s co-lead, stated that the center would bring more scientific expertise and rigor to study psychedelic therapy. Nemeroff is also the chair of the Department of Behavioral Sciences and Psychiatry at the Dell Medical School. The center, which is the first of its kind in the state, will allow researchers to…

MondayJan 10, 2022 12:21 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…

MondayJan 10, 2022 12:04 pm

Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector

Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his…

MondayJan 10, 2022 10:26 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 1:38 pm

A Recap of How Psychedelics Fared in 2021

At the start of last year, only a few psychedelic companies were trading on the exchange markets, with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”) among them. However, this year saw a number of IPOs, which increased the total number of public psychedelic companies trading on the market. These companies include Atai Life Sciences (NASDAQ: ATAI), Field Trip Health (NASDAQ: FTRP) and Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF). This increase brought more resources to the space, which helped ensure its survival. In addition, it widened the scope of treatments being researched as well as the…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

ThursdayJan 06, 2022 12:00 pm

Clinical Psychologists Cautiously Evaluating Psychedelic-Backed Mental Health Treatment

A new survey has found that mental health professionals believe that psychedelic substances possess psychological benefits. This was despite concerns about the potential neurocognitive and psychiatric risks linked to using psychedelic treatment. Gabrielle Agin-Liebes, the author of the study, stated that while there was a lot of interest in the potential use of psychedelics in clinical care, there also existed a lot of negative attitudes toward psychedelic therapy. She explained that understanding the extent to which psychedelic treatments would be accepted in the healthcare system would help advance the clinical use of these drugs once they received approval for medical…

ThursdayJan 06, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key Meeting with UK Regulatory Agency

Meeting takes company a step closer to advancing its lead investigational candidate CYB003 into clinical development CYB003 is designed for the treatment of two significant conditions: major depressive disorder (“MDD”) and alcohol use disorder (“AUD”) CEO notes that CYB003 has the potential to achieve better patient outcomes The coming year holds significant promise for Cybin (NEO: CYBN) (NYSE American: CYBN) for numerous reasons. The biopharmaceutical company has seen significant success in the execution of its strategic focus on progressing psychedelics to therapeutics, including its recent announcement that company representatives will hold a scientific advice meeting with the UK Medical and Healthcare…

WednesdayJan 05, 2022 1:45 pm

Study Finds Psilocybin-Assisted Psychotherapy Effective in Treating Suicidal Ideation in Cancer Patients

Patients with cancer have a high risk of suicidal ideation and suicide, in particular patients in the advanced stages. These individuals often experience a loss of meaning in life and existential distress, which isn’t easily remedied through the use of pharmacological treatments. However, a new study has found that psilocybin when used together with psychotherapy may alleviate suicidal ideation in patients with life-threatening cancers. The improvements observed in patient mental health were maintained months and even years after treatment had been administered. The study’s findings were reported in the “ACS Pharmacology & Translational Science” journal. The researchers, led by Stephen…

WednesdayJan 05, 2022 11:53 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Entering 2022 With Multiple Clinical Trials Including MYCO-001 for Smoking Cessation

Mydecine has partnered with Dr. Matthew Johnson and Johns Hopkins University for two upcoming trials for MYCO-001 – a psilocybin approach to smoking cessation The company is positioned to fill a billion-dollar hole in the industry after the leading pharmaceutical Chantix was removed from the market due to cancer risks Two previous psilocybin trials conducted by Dr. Johnson, show promising results for the use of psilocybin as a smoking cessation tool when paired with cognitive behavioral therapy (“CBT”) Smoking remains among the leading public health concerns of the 21st century. The total number of tobacco-related deaths worldwide has reached six…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000